China Medical System Holdings Limited (HKG:0867)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 34.99B +102.5% |
| Revenue (ttm) | 8.61B +12.1% |
| Net Income | 1.81B +18.7% |
| EPS | 0.75 +20.1% |
| Shares Out | 2.42B |
| PE Ratio | 19.35 |
| Forward PE | 17.04 |
| Dividend | 0.30 (2.06%) |
| Ex-Dividend Date | Aug 29, 2025 |
| Volume | 3,059,199 |
| Average Volume | 3,814,066 |
| Open | 14.45 |
| Previous Close | 14.48 |
| Day's Range | 14.28 - 14.78 |
| 52-Week Range | 6.83 - 15.63 |
| Beta | 1.25 |
| RSI | 61.50 |
| Earnings Date | Mar 16, 2026 |
About HKG:0867
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China. The company offers cardio-cerebrovascular products include VELPHORO, a sucroferric oxyhydroxide chewable tablets and diazepam nasal spray for seizure clusters; XinHuoSu, a recombinant human brain natriuretic peptide for acute heart failure; Plendil, a felodipine sustained release tablets for hypertension; and Deanxit, a flupentixol and melitracen tablets for mild-to-moderate ... [Read more]
Financial Performance
In 2024, HKG:0867's revenue was 7.47 billion, a decrease of -6.79% compared to the previous year's 8.01 billion. Earnings were 1.62 billion, a decrease of -32.54%.
Financial numbers in CNY Financial StatementsNews
CMS (867.HK/8A8.SG): Innovative Drug Oral JAK1 Inhibitor Povorcitinib Has Been Included in the List of Breakthrough Therapeutic Drugs in China
SHENZHEN, CHINA, Dec. 15, 2025 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an i...
CMS (867.HK; 8A8.SG) Signed A Distribution Agreement for Ophthalmic Drugs Lucentis® and Beovu®
SHENZHEN, CHINA, Oct. 27, 2025 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 27 October 2025, the Group through its subsidiary CMS VI...
Alpha Cognition Announces Partner China Medical System Has NDA Accepted in China for the Review of ZUNVEYL® (Benzgalantamine) for Alzheimer’s Disease
VANCOUVER, British Columbia & DALLAS — Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” [ACI], or the “Company”), a biopharmaceutical company developing novel therapies for debilitating neurodeg...
Alpha Cognition Inks $44 Million Licensing Pact For Its Alzheimer's Drug In China
On Wednesday, Alpha Cognition Inc. (NASDAQ: ACOG) and China Medical System Holdings Limited announced an exclusive licensing agreement for the development, manufacturing, and commercialization of Zun...